Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 4,919,494 shares, a decline of 12.2% from the October 15th total of 5,601,071 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average daily trading volume, of 639,577 shares, the short-interest ratio is presently 7.7 days.
NAVB stock remained flat at $$0.22 during trading on Friday. 235,556 shares of the company were exchanged, compared to its average volume of 373,018. Navidea Biopharmaceuticals has a one year low of $0.13 and a one year high of $0.47.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The company had revenue of $0.23 million for the quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/11/09/navidea-biopharmaceuticals-inc-navb-short-interest-update.html.
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.